|
JP2000505650A
(ja)
*
|
1996-02-08 |
2000-05-16 |
アメリカ合衆国 |
樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
|
|
US6734014B1
(en)
|
1996-02-08 |
2004-05-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods and compositions for transforming dendritic cells and activating T cells
|
|
EP0906444A1
(de)
*
|
1996-04-19 |
1999-04-07 |
Gabriele Pecher |
Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
|
|
ATE421888T1
(de)
*
|
1997-08-13 |
2009-02-15 |
Uab Research Foundation |
Impfung durch topische verwendung genetischer vektoren
|
|
GB2370571B
(en)
*
|
1998-11-18 |
2003-05-07 |
Oxford Biomedica Ltd |
A modified 5t4 antigen
|
|
EP1165144A2
(en)
*
|
1999-03-15 |
2002-01-02 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
|
CA2309313A1
(en)
*
|
1999-08-05 |
2001-02-05 |
Board Of Trustees Of The University Of Arkansas |
Stimulation of the immune response by human dendritic cell manipulation
|
|
WO2001027156A1
(en)
*
|
1999-10-08 |
2001-04-19 |
Curagen Corporation |
Interleukin-2 like protein and nucleic acids encoding same
|
|
US8128922B2
(en)
*
|
1999-10-20 |
2012-03-06 |
Johns Hopkins University |
Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
|
|
GB0007150D0
(en)
*
|
2000-03-24 |
2000-05-17 |
Lamellar Therapeutics Limited |
Immunotherapeutic methods and compositions
|
|
EP1363938B1
(en)
|
2000-08-03 |
2013-12-11 |
Johns Hopkins University |
Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
|
|
US20030113919A1
(en)
*
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
|
EP1644048B1
(en)
|
2003-05-05 |
2015-04-29 |
Johns Hopkins University |
Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
|
|
GB0322448D0
(en)
|
2003-09-25 |
2003-10-29 |
Lamellar Therapeutics Ltd |
Using lamellar bodies to modify linear biological macro molecules
|
|
WO2006073970A2
(en)
|
2005-01-06 |
2006-07-13 |
The Johns Hopkins University |
Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
|
|
WO2006124700A2
(en)
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
|
US9085638B2
(en)
|
2007-03-07 |
2015-07-21 |
The Johns Hopkins University |
DNA vaccine enhancement with MHC class II activators
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
WO2008153802A1
(en)
*
|
2007-05-29 |
2008-12-18 |
Eusa Pharma, Inc. |
Ex-vivo treatment of cancer using psma and antibodies thereto
|
|
AU2009236306B2
(en)
|
2008-04-17 |
2015-04-02 |
Pds Biotechnology Corporation |
Stimulation of an immune response by enantiomers of cationic lipids
|
|
WO2013039989A1
(en)
*
|
2011-09-12 |
2013-03-21 |
Pds Biotechnology Corporation |
Particluate vaccine formulations
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US10286064B2
(en)
|
2012-06-15 |
2019-05-14 |
Pds Biotechnology Corporation |
Cationic lipid vaccine compositions and methods of use
|
|
AU2013317805B2
(en)
|
2012-09-21 |
2018-07-26 |
Pds Biotechnology Corporation |
Improved vaccine compositions and methods of use
|
|
US11612652B2
(en)
|
2015-11-13 |
2023-03-28 |
Pds Biotechnology Corporation |
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
TW201924722A
(zh)
|
2017-12-05 |
2019-07-01 |
美商Ｐｄｓ生技公司 |
用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US12296023B2
(en)
|
2018-08-16 |
2025-05-13 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|